Compare EOG Resources Inc (EOG) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs Tango Therapeutics Inc. — how do they compare? EOG Resources Inc trades at $155 (market cap $80.34B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: EOG Resources Inc is far larger — about 21.4× Tango Therapeutics Inc.'s market cap, and EOG Resources Inc pays a 2.66% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold EOG Resources Inc for 59 Days and Tango Therapeutics Inc. for 0 Days on average.
| EOG | TNGX | |
|---|---|---|
Market Cap | $80.34B | $3.75B |
Volume | 2,309,813 | 9,619,106 |
Sector | Energy | Health |
52-Week High | $154.19 | $32.90 |
52-Week Low | $101.78 | $7.50 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $83.69B | $2.77B |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $153.17, up 1.77% with strong technical momentum and bullish moving averages. The company maintains robust profitability with 25.81% net margins and consistent earnings beats, though revenue declined to $22.58B in 2025. Analyst consensus remains strongly positive with 59% buy ratings and a $163.50 price target, while recent CFO transition and dividend payments highlight stable corporate governance.
EOG presents a compelling value opportunity with attractive valuation multiples (P/E 11.92, EV/EBITDA 6.02) and strong cash generation. Key risks include oil price volatility and capital expenditure intensity, but disciplined capital allocation and projected 2026 revenue growth to $26.6B support upside potential toward analyst targets.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
